Company / Operating Margin
Editas Medicine, Inc. Operating Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-777.2%
FY2025
5-year range
-1146.3% / -148.6%
FY2021-FY2025
Trend
+32.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin returned to growth in FY2025 after 2 years of decline, reaching -777.2%.
Based on SEC 10-K filings.
-777.2% in FY2025 with a 5-year CAGR of -421.1%.
Declined from -756.1% to -777.2% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -628.6pp
- 5-Year Change
- -421.1pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin increased 32.2% year-over-year.
- Peak operating margin was recorded in FY2022.
- Lowest operating margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -777.2% | +32.2% |
| FY2024 | -1146.3% | -51.6% |
| FY2023 | -756.1% | -408.8% |
| FY2022 | -148.6% | +78.3% |
| FY2021 | -686.4% | -92.8% |
| FY2020 | -356.1% | +59.2% |
| FY2019 | -873.6% | +45.6% |
| FY2018 | -1605.6% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026